LONQUEX
LIPEGFILGRASTIM
What it does
Lipegfilgrastim is a medicine that helps the body produce more white blood cells, which are important for fighting infections.
Commonly used for: to prevent infections in people undergoing cancer treatment, to increase white blood cell counts after certain medical conditions
Read more in plain English ↓Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.
Ask about this medicine
Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.
Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.
Sourcing - Kenya onlyRegistration & product details
Source: South African Health Products Regulatory Authority · fetched 2026-04-15 21:25:15 · updated 2026-10-25 04:01:44
About this medicine
Lipegfilgrastim is a medicine that helps the body produce more white blood cells, which are important for fighting infections.
What it treats
- to prevent infections in people undergoing cancer treatment
- to increase white blood cell counts after certain medical conditions
How it works
It stimulates the bone marrow to produce more white blood cells, improving the body's ability to fight off infections.
Who it's for
It is used for patients receiving chemotherapy or those with certain health issues that lower white blood cell counts.
AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.
Clinical monograph: Lipegfilgrastim
BNF-referencedLipegfilgrastim is a glycopegylated recombinant methionyl human granulocyte-colony stimulating factor (G-CSF) that is used primarily as an immunostimulant to mobilize hematopoietic stem cells into peripheral blood for subsequent autologous transplantation in patients undergoing cytotoxic chemotherapy. It is designed to reduce the duration of neutropenia and the incidence of febrile neutropenia, particularly in patients with malignancies such as lymphoma or multiple myeloma.
Indications
- Mobilization of hematopoietic stem cells to peripheral blood for subsequent autologous transplantation in patients undergoing cytotoxic chemotherapy
- Reduction in duration of neutropenia and incidence of febrile neutropenia in patients with lymphoma or multiple myeloma
Dosage
Children: Refer to the BNF for Children for specific dosing guidelines.
Adults: 6 mg for each chemotherapy cycle, administered subcutaneously approximately 24 hours after chemotherapy. Maximum daily dose is 40 mg.
Mechanism of action
Lipegfilgrastim acts by binding to and activating the granulocyte-colony stimulating factor receptor (G-CSFR) on hematopoietic progenitor cells in the bone marrow. This stimulates the proliferation, differentiation, and mobilization of neutrophil precursors into circulation, thereby increasing the number of circulating neutrophils, which are crucial for the immune response.
Pharmacodynamics
The pharmacodynamic effects of Lipegfilgrastim include enhanced production of neutrophils, increased white blood cell counts, and improved recovery from myelosuppressive effects of chemotherapy. Its pharmacodynamic profile allows it to effectively reduce the duration of neutropenia and the risk of infections associated with low neutrophil counts.
Pharmacokinetics
Lipegfilgrastim exhibits dose-proportional pharmacokinetics. Following subcutaneous administration, it has a half-life of approximately 15 to 30 hours, allowing for once-daily dosing. Its bioavailability is high, and it is primarily eliminated through renal pathways. The pharmacokinetic profile may vary based on individual patient factors, including renal function, which may necessitate dose adjustments.
Contra-indications
- Acute leukaemia
- Hypersensitivity to the active substance or to any of the excipients
Adverse effects
- Chest pain
- Hypokalaemia
- Skin eruption
- Myalgia
- Nausea
- Flatulence
- Gastrointestinal discomfort
- Headache
- Hyperhidrosis
- Malaise
- Musculoskeletal pain
- Oral hypoaesthesia
- Sleep disorders
- Vomiting
- Postural hypotension
- Splenomegaly
- Syncope
- Glomerulonephritis
Interactions
- Myelosuppressive chemotherapy may increase the risk of adverse effects
Precautions
- Use effective contraception during treatment due to teratogenic effects observed in animal studies
- Monitor platelets and white blood cell count
- Caution is advised for patients regarding effects on driving and skilled tasks due to increased risk of dizziness, fatigue, or vasovagal reactions
- Dose adjustments may be necessary for patients with creatinine clearance of 20–50 mL/minute
Pregnancy
Manufacturer advises avoiding use due to teratogenic effects in animal studies.
Breast-feeding
Manufacturer advises avoiding use due to lack of information on excretion in human milk.
Storage
Store in a refrigerator (2°C to 8°C). Do not freeze. Keep the pre-filled syringe in the outer carton to protect from light.
Formulations
- Solution for injection: 10 mg per 1 ml (e.g., Neulasta 6mg/0.6ml)
- Pre-filled disposable injection
AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.